CRISPR Therapeutics AG, a company listed on the US stock exchange under the ticker CRSP.US, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC). This filing is part of the Schedule 14A, which is a proxy statement required by Section 14(a) of the Securities Exchange Act of 1934. The document indicates that CRISPR Therapeutics is the registrant and there are no other parties filing the proxy statement. The company has confirmed that no filing fee is required for this submission.

CRISPR Therapeutics AG, a company listed on the US stock exchange under the ticker CRSP.US, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC). This filing is part of the Schedule 14A, which is a proxy statement required by Section 14(a) of the Securities Exchange Act of 1934. The document indicates that CRISPR Therapeutics is the registrant and there are no other parties filing the proxy statement. The company has confirmed that no filing fee is required for this submission.